辛芩颗粒治疗变应性鼻炎的随机对照试验的系统评价

Xinqin Granule in the treatment of allergic rhinitis: a systematic review of randomized clincal trials

关键词:  辛芩颗粒  变应性鼻炎  系统评价  Meta分析  随机对照试验

Key words:  Xinqin Granule  allergic rhinitis  systematic review  Meta analysis  randomized clincal trial

摘要:

[目的] 系统评价辛芩颗粒治疗变应性鼻炎的随机对照试验。[方法] 计算机检索维普（VIP）、万方医学网（WanFang）、中国生物医学文献数据库（CBM）、中国知网（CNKI）、Embase、the Cochrane Library、PubMed数据库，搜集辛芩颗粒治疗变应性鼻炎的随机对照试验（RCT），检索时限均为建库至2019年12月。文献由2名研究者独立筛选、提取资料并对纳入研究的偏倚风险进行评价。文献参照Cochrane Handbook 5.3推荐的偏倚风险评估工具进行风险评估，采用RevMan 5.3软件进行Meta分析。[结果] 共纳入10个RCT，Meta分析结果显示：相对于单纯用口服西药，辛芩颗粒联合口服西药治疗变应性鼻炎可以提高临床总有效率[RR=1.18，95% CI（1.13，1.24），P<0.000 01]；降低变应性鼻炎的复发率[RR=0.29，95% CI（0.20，0.41），P<0.000 01]；降低不良反应的发生率[RR=0.54，95% CI（0.32，0.92），P=0.02]。[结论] 辛芩颗粒在治疗变应性鼻炎时，可提高临床总有效率、减少复发、减少不良反应的发生。受纳入研究质量和数量的限制，上述结论尚待更多更严谨的临床试验予以验证。

Abstract:

[Objective] To systematically review the randomized controlled trials of Xinqin Granules in the treatment of allergic rhinitis.[Methods] VIP, WanFang, CBM, CNKI, EMbase, the Cochrane Library, and PubMed databases were retrieved online to collect randomized controlled trials (RCT) of Xinqin Granules in treatment for allergic rhinitis since the establishment to December 2019. Two investigators screened out literature independently, extracted data and assessed the risk of bias of included studies. The risk assessment of included references was made according to criteria recommended by Cochrane Handbook 5.3.Meta-analysis was performed by RevMan 5.3 software.[Results] A total of 10 RCT were included. Meta analysis showed that:compared with oral western medicine alone, Xinqin Granules combined with oral Western medicine in treating allergic rhinitis can improve the total clinical effective rate[RR=1.18, 95%CI(1.13, 1.24), P<0.000 01], reduce the relapse rate of allergic rhinitis[RR=0.29, 95%CI(0.20, 0.41), P<0.000 01], and reduce the incidence of adverse reactions[RR=0.54, 95%CI(0.32, 0.92), P=0.02].[Conclusion] Xinqin Granules have significant effects in the treatment of allergic rhinitis in the total clinical effective rate, reducing recurrence, reducing the occurrence of adverse reactions. Due to the limited by the quality and quantity of the included studies, the above conclusions are yet to be verified by more rigorous clinical trials.